Evidence map›Paper›PMID 41471745›Full record

ArticleMolecules (Basel, Switzerland)2025

New Quinazolin-4(3

Raluca Pele, Gabriel Marc, Brîndușa Tiperciuc, Ioana Ionuț, Anca Stana, Cristina Moldovan, Corina Tatomir, Oana Maria Dragostin, Adrian Pîrnău, Laurian Vlase and 2 more

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Raluca PeleDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, "Iuliu Hațieganu" University of Medicine and Pharmacy, 41 Victor Babeș Street, 400012 Cluj-Napoca, Romania.ORCID 0000-0002-6807-5135
Gabriel MarcDepartment of Organic Chemistry, Faculty of Pharmacy, "Iuliu Hațieganu" University of Medicine and Pharmacy, 41 Victor Babeș Street, 400012 Cluj-Napoca, Romania.ORCID 0000-0001-9397-0388
Brîndușa TiperciucDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, "Iuliu Hațieganu" University of Medicine and Pharmacy, 41 Victor Babeș Street, 400012 Cluj-Napoca, Romania.ORCID 0000-0002-1333-5649
Ioana IonuțDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, "Iuliu Hațieganu" University of Medicine and Pharmacy, 41 Victor Babeș Street, 400012 Cluj-Napoca, Romania.
Anca StanaDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, "Iuliu Hațieganu" University of Medicine and Pharmacy, 41 Victor Babeș Street, 400012 Cluj-Napoca, Romania.ORCID 0000-0002-8453-3642
Cristina MoldovanDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, "Iuliu Hațieganu" University of Medicine and Pharmacy, 41 Victor Babeș Street, 400012 Cluj-Napoca, Romania.
Corina TatomirDepartment of Radiobiology and Tumor Biology, "Prof. Dr. Ion Chiricuță" Oncology Institute, 34-36 Republicii Street, 400015 Cluj-Napoca, Romania.
Oana Maria DragostinResearch Centre in the Medical-Pharmaceutical Field, Faculty of Medicine and Pharmacy, "Dunărea de Jos" University of Galați, 47 Domneasca Street, 800008 Galați, Romania.
Adrian PîrnăuNational Institute for Research and Development of Isotopic and Molecular Technologies, 67-103 Donath Street, 400293 Cluj-Napoca, Romania.ORCID 0000-0002-2313-9350
Laurian VlaseDepartment of Pharmaceutical Technology and Biopharmaceutics, "Iuliu Hațieganu" University of Medicine and Pharmacy, 41 Victor Babeș Street, 400012 Cluj-Napoca, Romania.ORCID 0000-0002-0664-3387
Daniel UngureanuDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, "Iuliu Hațieganu" University of Medicine and Pharmacy, 41 Victor Babeș Street, 400012 Cluj-Napoca, Romania.ORCID 0000-0001-5980-6963
Ovidiu OnigaDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, "Iuliu Hațieganu" University of Medicine and Pharmacy, 41 Victor Babeș Street, 400012 Cluj-Napoca, Romania.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Three new 2,3-disubstituted quinazolin-4(3

Indexed as

Antineoplastic AgentsQuinazolinonesVascular Endothelial Growth Factor Receptor-2Cell ProliferationCell SurvivalDrug Screening Assays, AntitumorHep G2 CellsHumansMolecular Docking SimulationMolecular StructureProtein Kinase InhibitorsSorafenibStructure-Activity RelationshipAntineoplastic AgentsKDR protein, humanProtein Kinase InhibitorsQuinazolinonesSorafenibVascular Endothelial Growth Factor Receptor-2HepG2 cell linemolecular dockingquinazolin-4(3H)-onesorafenibVEGFR-2

Identifiers

PMID41471745
PMCPMC12736141

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.